As scientists continue to unravel the biology of aging, one of the most intriguing discoveries has been the identification of "biological clocks"- molecular markers that track how our bodies change over time. Variation in these markers between individuals has offered remarkable insights into the risk of adverse outcomes, including mortality and age-related chronic diseases.

Among the earliest of these markers to be discovered were telomeres, the protective caps at the ends of chromosomes. While telomeres don't fully explain the mystery of aging and are no longer considered the most accurate indicators of biological age, they offer a unique window into cellular mortality. Their significance lies in the fact that they shorten with each cell division, ultimately limiting a cell's lifespan.

Another leap forward came with the development of epigenetic clocks, which measure DNA methylation- tiny chemical tags that regulate gene activity and change with remarkable regularity over time. The first multi-tissue clock, introduced by Steve Horvath in 2013, enabled estimation of biological age across nearly any human tissue using methlyation patterns at specific CpG sites. Since then, numerous next-generation clocks, such as PhenoAge, GrimAge, and DunedinPACE- have improved accuracy and predictive power for morbidity an mortality by integrating molecular, clinical, and functional data. Yet, as Meyer et al. (2025) emphasize in a scientific article, the precision of these clocks should not be mistaken for evidence of a programmed biological timetable. Rather, they likely capture the cumulative signatures of stochastic molecular damage, imperfect repair, and environmental stress that accompany aging.

At the same time, scientists are uncovering the role of chronic inflammation, or "inflammaging" as a key process driving the wear and tear of aging tissues. A scientific article by Claudio Franceschi and colleagues explores how lifelong immune activation might contribute to frailty, heart disease, and neurodegeneration, and how understanding this could open the door to new therapies.

Finally, while many companies now offer biological age tests, researchers caution that these tools are not yet ready for personal health assessment. A news article discusses both the promises and pitfalls of turning complex biology into consumer products- and why we still have more to learn before these measures can truly guide personalized healthcare.